-
2
-
-
14844291419
-
Characteristics and outcomes of patients hospitalised for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated HEart failure national REgistry (ADHERE)
-
for the ADHERE Scientific Advisory Committee and Investigators
-
Adams KF, Fonarow GC, Emerman CL et al; for the ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalised for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated HEart failure national REgistry (ADHERE). Am. Heart J. 149, 209-213 (2005).
-
(2005)
Am. Heart J.
, vol.149
, pp. 209-213
-
-
Adams, K.F.1
Fonarow, G.C.2
Emerman, C.L.3
-
3
-
-
0036915820
-
Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study
-
Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J. 144, 1102-1108 (2002).
-
(2002)
Am. Heart J.
, vol.144
, pp. 1102-1108
-
-
Burger, A.J.1
Horton, D.P.2
LeJemtel, T.3
-
4
-
-
29344447073
-
Role of diminished renal function in cardiovascular mortality
-
Schrier RW. Role of diminished renal function in cardiovascular mortality. J. Am. Coll. Cardiol. 47, 1-8 (2006).
-
(2006)
J. Am. Coll. Cardiol.
, vol.47
, pp. 1-8
-
-
Schrier, R.W.1
-
5
-
-
10744231948
-
Relationship between heart failure treatment and development of worsening renal function among hospitalized patients
-
Butler J, Forman D, Abram W et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am. Heart J. 147, 331-338 (2004).
-
(2004)
Am. Heart J.
, vol.147
, pp. 331-338
-
-
Butler, J.1
Forman, D.2
Abram, W.3
-
6
-
-
27644543953
-
Therapeutics in congestive heart failure: From hemodynamics to neurohormones
-
In: Singh PK, Dixon I, Kirschenbaum LA, Dhalla NS (Eds). Kluwer Academic Publishers, MA, USA
-
Goldsmith SR. Therapeutics in congestive heart failure: from hemodynamics to neurohormones. In: Cardiac Remodeling and Failure. Singh PK, Dixon I, Kirschenbaum LA, Dhalla NS (Eds). Kluwer Academic Publishers, MA, USA 17-34 (2003).
-
(2003)
Cardiac Remodeling and Failure
, pp. 17-34
-
-
Goldsmith, S.R.1
-
7
-
-
2742581427
-
Renal sodium excretion, edematous disorders, and diuretic use
-
In: Schrier RW (Ed.). Lippincott Williams and Wilkins, PA, USA
-
Schrier RW, Gurevich A, Abraham W. Renal sodium excretion, edematous disorders, and diuretic use. In: Renal and Electrolyte Disorders. (6th Edition). Schrier RW (Ed.). Lippincott Williams and Wilkins, PA, USA 64-114 (2002).
-
(2002)
Renal and Electrolyte Disorders. (6th Edition)
, pp. 64-114
-
-
Schrier, R.W.1
Gurevich, A.2
Abraham, W.3
-
8
-
-
33644871184
-
Hyponatremia in patients with heart failure
-
De Luca L, Klein L, Udelson JE et al. Hyponatremia in patients with heart failure. Am. J. Cardiol. 96(12A), 19L-23L (2005).
-
(2005)
Am. J. Cardiol.
, vol.96
, Issue.12 A
-
-
De Luca, L.1
Klein, L.2
Udelson, J.E.3
-
9
-
-
18844423537
-
Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study
-
OPTIME-CHF Investigators
-
Klein L, O'Connor CM, Leimberger JD et al, OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111(l9), 2454-2460 (2005).
-
(2005)
Circulation
, vol.111
, Issue.19
, pp. 2454-2460
-
-
Klein, L.1
O'Connor, C.M.2
Leimberger, J.D.3
-
10
-
-
0019861237
-
Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure
-
Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N. Engl. J. Med. 305, 263-266 (1981).
-
(1981)
N. Engl. J. Med.
, vol.305
, pp. 263-266
-
-
Szatalowicz, V.L.1
Arnold, P.E.2
Chaimovitz, C.3
Bichet, D.4
Schrier, R.W.5
-
11
-
-
0020617013
-
Increased plasma arginine vasopressin levels in patients with congestive heart failure
-
Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. 1, 1385-1390 (1983).
-
(1983)
J. Am. Coll. Cardiol.
, vol.1
, pp. 1385-1390
-
-
Goldsmith, S.R.1
Francis, G.S.2
Cowley, A.W.3
Levine, T.B.4
Cohn, J.N.5
-
12
-
-
0014279821
-
Plasma ADH level in patients with chronic congestive heart failure
-
Yamane Y. Plasma ADH level in patients with chronic congestive heart failure. Japan Circ. J. 32, 745-759 (1968).
-
(1968)
Japan Circ. J.
, vol.32
, pp. 745-759
-
-
Yamane, Y.1
-
13
-
-
0022512331
-
Hemodynamic effects of infused arginine vasopressin in congestive heart failure
-
Goldsmith SR, Francis GS, Cowley AW, Goldenberg I, Cohn JN. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J. Am. Coll. Cardiol. 8, 779-783 (1986).
-
(1986)
J. Am. Coll. Cardiol.
, vol.8
, pp. 779-783
-
-
Goldsmith, S.R.1
Francis, G.S.2
Cowley, A.W.3
Goldenberg, I.4
Cohn, J.N.5
-
14
-
-
0031703592
-
Recent advances in the understanding of water metabolism in heart failure
-
Schrier RW, Martin PY. Recent advances in the understanding of water metabolism in heart failure. Adv. Exp. Med. Biol. 449, 415-426 (1998).
-
(1998)
Adv. Exp. Med. Biol.
, vol.449
, pp. 415-426
-
-
Schrier, R.W.1
Martin, P.Y.2
-
15
-
-
0010659406
-
Baroreflex control of vasopressin secretion in normal humans
-
In: Cowley AW, Liard J-F, Ausiello DA (Eds). Raven Press, NY, USA
-
Goldsmith SR. Baroreflex control of vasopressin secretion in normal humans. In: Vasopressin: Cellular and Integrative Functions. Cowley AW, Liard J-F, Ausiello DA (Eds). Raven Press, NY, USA 389-397 (1988).
-
(1988)
Vasopressin: Cellular and Integrative Functions
, pp. 389-397
-
-
Goldsmith, S.R.1
-
16
-
-
33947633785
-
Central catecholamine pathways to vasopressin neurons
-
In: Schrier RW (Ed.). Raven Press NY, USA
-
Sladek JR Jr. Central catecholamine pathways to vasopressin neurons. In: Vasopressin. Schrier RW (Ed.). Raven Press NY, USA 343-352 (1985).
-
(1985)
Vasopressin
, pp. 343-352
-
-
Sladek Jr., J.R.1
-
17
-
-
0033373438
-
Vasopressin: A therapeutic target in congestive heart failure?
-
Goldsmith SR. Vasopressin: a therapeutic target in congestive heart failure? J. Card. Fail. 5, 347-356 (1999).
-
(1999)
J. Card. Fail.
, vol.5
, pp. 347-356
-
-
Goldsmith, S.R.1
-
18
-
-
0023795642
-
Mechanisms of action of vasopressin and vasopressin antagonists
-
Jard S. Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int. Suppl. 26, S38-S42 (1988).
-
(1988)
Kidney Int. Suppl.
, vol.26
-
-
Jard, S.1
-
19
-
-
0025820750
-
+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors
-
+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ. Res. 69, 239-245 (1991).
-
(1991)
Circ. Res.
, vol.69
, pp. 239-245
-
-
Xu, Y.J.1
Gopalakrishnan, V.2
-
20
-
-
0034629529
-
Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor
-
Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor. Eur. J. Pharmacol. 391, 39-48 (2000).
-
(2000)
Eur. J. Pharmacol.
, vol.391
, pp. 39-48
-
-
Nakamura, Y.1
Haneda, T.2
Osaki, J.3
Miyata, S.4
Kikuchi, K.5
-
21
-
-
0022461967
-
Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit
-
Arnolda L, McGrath BP, Cocks M, Johnston CI. Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit. J. Clin. Invest. 78, 674-679 (1986).
-
(1986)
J. Clin. Invest.
, vol.78
, pp. 674-679
-
-
Arnolda, L.1
McGrath, B.P.2
Cocks, M.3
Johnston, C.I.4
-
22
-
-
4243805674
-
Hemodynamic effects of vasopressin inhibition in congestive heart failure
-
Stone CK, Imai N, Thomas A, Sladek CD, Liang CS, Hood WB. Hemodynamic effects of vasopressin inhibition in congestive heart failure. Clin. Res. 34, 632A (1986).
-
(1986)
Clin. Res.
, vol.34
-
-
Stone, C.K.1
Imai, N.2
Thomas, A.3
Sladek, C.D.4
Liang, C.S.5
Hood, W.B.6
-
23
-
-
0028558373
-
Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
-
Naitoh M, Suzuki H, Murakami M et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol, 267, H2245-H2254 (1994).
-
(1994)
Am. J. Physiol.
, vol.267
-
-
Naitoh, M.1
Suzuki, H.2
Murakami, M.3
-
24
-
-
0027296317
-
Biochemical and pharmacologic properties of SR 49059, a new potent nonpeptide antagonist of rat and human vasopression V1 receptors
-
Serradeil-Ledel C, Wagon J, Garcia G et al. Biochemical and pharmacologic properties of SR 49059, a new potent nonpeptide antagonist of rat and human vasopression V1 receptors. J. Clin. Invest. 92, 224-231 (1993).
-
(1993)
J. Clin. Invest.
, vol.92
, pp. 224-231
-
-
Serradeil-Ledel, C.1
Wagon, J.2
Garcia, G.3
-
25
-
-
0035856509
-
Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure
-
Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104, 2417-2423 (2001).
-
(2001)
Circulation
, vol.104
, pp. 2417-2423
-
-
Udelson, J.E.1
Smith, W.B.2
Hendrix, G.H.3
-
26
-
-
11144355788
-
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial (ACTIV)
-
for the Acute and Chronic Therapeutic Impact of a Vasopressin antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators
-
Gheorghiade M, Gattis WA, O'Connor CM et al, for the Acute and Chronic Therapeutic Impact of a Vasopressin antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV). JAMA 291, 1963-1971 (2004).
-
(2004)
JAMA
, vol.291
, pp. 1963-1971
-
-
Gheorghiade, M.1
Gattis, W.A.2
O'Connor, C.M.3
-
27
-
-
0037904417
-
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure
-
Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation 107, 2690-2696 (2003).
-
(2003)
Circulation
, vol.107
, pp. 2690-2696
-
-
Gheorghiade, M.1
Niazi, I.2
Ouyang, J.3
-
28
-
-
0022653171
-
Hospital associated hyponatremia
-
Anderson RJ. Hospital associated hyponatremia. Kidney Int. 29, 1237-1247 (1986).
-
(1986)
Kidney Int.
, vol.29
, pp. 1237-1247
-
-
Anderson, R.J.1
-
29
-
-
0029816077
-
Correlates of major complications or death in patients admitted to the hospital with congestive heart failure
-
Chin MW, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch. Intern. Med. 156, 1814-1820 (1996).
-
(1996)
Arch. Intern. Med.
, vol.156
, pp. 1814-1820
-
-
Chin, M.W.1
Goldman, L.2
-
30
-
-
0022637771
-
Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure
-
Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation 73, 257-267 (1986).
-
(1986)
Circulation
, vol.73
, pp. 257-267
-
-
Lee, W.H.1
Packer, M.2
-
31
-
-
33751005260
-
SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia
-
Schrier RW, Gross P, Gheorghiade M et al; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355(20), 2099-2112 (2006).
-
(2006)
N. Engl. J. Med.
, vol.355
, Issue.20
, pp. 2099-2112
-
-
Schrier, R.W.1
Gross, P.2
Gheorghiade, M.3
-
32
-
-
0037223321
-
A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial
-
Wong F, Blei AT, Blendis LM et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37, 182-191 (2003).
-
(2003)
Hepatology
, vol.37
, pp. 182-191
-
-
Wong, F.1
Blei, A.T.2
Blendis, L.M.3
-
33
-
-
33947646654
-
Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: Insights from the Acute and Chronic Therapeutic Impact of a Vasopressin antagonist in Chronic Heart Failure (ACTIV in CHF) trial
-
(Abtstract)
-
Gheorghiade M, Adams K, O'Connor C et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin antagonist in Chronic Heart Failure (ACTIV in CHF) trial. J. Am. Coll. Cardiol. 145A (2005) (Abtstract).
-
(2005)
J. Am. Coll. Cardiol.
, vol.145 A
-
-
Gheorghiade, M.1
Adams, K.2
O'Connor, C.3
-
34
-
-
20944445209
-
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)
-
Gheorghiade M, Orlandi C, Burnett JC et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J. Card. Fail. 11, 260-269 (2005).
-
(2005)
J. Card. Fail.
, vol.11
, pp. 260-269
-
-
Gheorghiade, M.1
Orlandi, C.2
Burnett, J.C.3
-
35
-
-
0037221858
-
Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial
-
Russell SD, Selaru P, Pyne DA et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial. Am. Heart J. 145, 179-186 (2003).
-
(2003)
Am. Heart J.
, vol.145
, pp. 179-186
-
-
Russell, S.D.1
Selaru, P.2
Pyne, D.A.3
-
36
-
-
2742581427
-
Renal sodium excretion, edematous disorders, and diuretic use
-
In: Schrier RW (Ed.). Lippincott Williams and Wilkins, PA, USA
-
Schrier RW, Gurevich AK, Abraham WT. Renal sodium excretion, edematous disorders, and diuretic use. In: Renal and Electrolyte Disorders (6th Edition). Schrier RW (Ed.). Lippincott Williams and Wilkins, PA, USA 72-73 (2003).
-
(2003)
Renal and Electrolyte Disorders (6th Edition)
, pp. 72-73
-
-
Schrier, R.W.1
Gurevich, A.K.2
Abraham, W.T.3
-
37
-
-
0033955058
-
Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure
-
Gottlieb S, Skettino SL, Wolff A et al. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J. Am. Coll. Cardiol. 35, 56-59 (2000).
-
(2000)
J. Am. Coll. Cardiol.
, vol.35
, pp. 56-59
-
-
Gottlieb, S.1
Skettino, S.L.2
Wolff, A.3
-
38
-
-
33947682516
-
Chronic diuretics, renal dysfunction raise mortality risk in decompensated heart failure
-
Presented at: New Orleans, LA, USA, 7-10 March
-
Aronson D. Chronic diuretics, renal dysfunction raise mortality risk in decompensated heart failure. Presented at: American College of Cardiology 2004 Scientific Sessions New Orleans, LA, USA, 7-10 March, 2004.
-
(2004)
American College of Cardiology 2004 Scientific Sessions
-
-
Aronson, D.1
-
39
-
-
9144262490
-
Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure
-
Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol, 43, 61-67 (2004).
-
(2004)
J. Am. Coll. Cardiol.
, vol.43
, pp. 61-67
-
-
Forman, D.E.1
Butler, J.2
Wang, Y.3
-
40
-
-
0032799699
-
Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure
-
Weinfeld MS, Chertow GM, Stevenson LW, Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am. Heart J. 138, 285-290 (1999).
-
(1999)
Am. Heart J.
, vol.138
, pp. 285-290
-
-
Weinfeld, M.S.1
Chertow, G.M.2
Stevenson, L.W.3
-
41
-
-
0034636845
-
Renal function, neurohormonal activation, and survival in patients with chronic heart failure
-
Hillege HL, Girbes, AR, de Kam P et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102, 203-210 (2000).
-
(2000)
Circulation
, vol.102
, pp. 203-210
-
-
Hillege, H.L.1
Girbes, A.R.2
de Kam, P.3
-
42
-
-
33947656199
-
Chronic diuretics, renal dysfunction raise mortality risk in decompensated heart failure
-
Presented at: New Orleans, LA, USA, 7-10 March
-
Costanzo MR. Chronic diuretics, renal dysfunction raise mortality risk in decompensated heart failure. Presented at: American College of Cardiology 2004 Scientific Sessions New Orleans, LA, USA, 7-10 March, 2004.
-
(2004)
American College of Cardiology 2004 Scientific Sessions
-
-
Costanzo, M.R.1
-
43
-
-
0033592418
-
Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction
-
Cooper HA, Dries DL, Davis CE et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100, 1311-1315 (1999).
-
(1999)
Circulation
, vol.100
, pp. 1311-1315
-
-
Cooper, H.A.1
Dries, D.L.2
Davis, C.E.3
|